11-108343337-ATTTCAGTGCC-A

Variant summary

Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong

The NM_000051.4(ATM):​c.8395_8404del​(p.Phe2799LysfsTer4) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,613,922 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000012 ( 0 hom. )

Consequence

ATM
NM_000051.4 frameshift

Scores

Not classified

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:21

Conservation

PhyloP100: 3.29
Variant links:
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]
C11orf65 (HGNC:28519): (chromosome 11 open reading frame 65) Predicted to be involved in negative regulation of mitochondrial fission and negative regulation of protein targeting to mitochondrion. Predicted to be located in cytosol and mitochondrial outer membrane. [provided by Alliance of Genome Resources, Apr 2022]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 16 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 11-108343337-ATTTCAGTGCC-A is Pathogenic according to our data. Variant chr11-108343337-ATTTCAGTGCC-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 186242.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-108343337-ATTTCAGTGCC-A is described in Lovd as [Pathogenic]. Variant chr11-108343337-ATTTCAGTGCC-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
ATMNM_000051.4 linkuse as main transcriptc.8395_8404del p.Phe2799LysfsTer4 frameshift_variant 57/63 ENST00000675843.1 NP_000042.3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
ATMENST00000675843.1 linkuse as main transcriptc.8395_8404del p.Phe2799LysfsTer4 frameshift_variant 57/63 NM_000051.4 ENSP00000501606 P1

Frequencies

GnomAD3 genomes
AF:
0.0000131
AC:
2
AN:
152210
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000199
AC:
5
AN:
251232
Hom.:
0
AF XY:
0.0000295
AC XY:
4
AN XY:
135770
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000327
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000264
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.0000123
AC:
18
AN:
1461712
Hom.:
0
AF XY:
0.0000138
AC XY:
10
AN XY:
727158
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000232
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000135
Gnomad4 OTH exome
AF:
0.0000166
GnomAD4 genome
AF:
0.0000131
AC:
2
AN:
152210
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74354
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000294
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000712
Hom.:
0
Bravo
AF:
0.0000189
Asia WGS
AF:
0.000289
AC:
1
AN:
3478

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:21
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Ataxia-telangiectasia syndrome Pathogenic:6
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpFeb 10, 2020Variant summary: ATM c.8395_8404del10 (p.Phe2799LysfsX4) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 2e-05 in 251232 control chromosomes (gnomAD). c.8395_8404del10 has been reported in the literature in homozygous and compound heterozygous individuals affected with Ataxia-Telangiectasia (e.g. Nahas_2009, Mitui_2003, Soukupova_2011). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, and demonstrated the most pronounced variant effect results in <10% of normal phosphorylation activity (Nahas_2009). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic (4x) or likely pathogenic (1x). Based on the evidence outlined above, the variant was classified as pathogenic. -
Likely pathogenic, criteria provided, single submitterclinical testingCounsylOct 13, 2015- -
Pathogenic, criteria provided, single submitterclinical testingBaylor Genetics-- -
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 30, 2024This sequence change creates a premature translational stop signal (p.Phe2799Lysfs*4) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is present in population databases (rs761367329, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with ataxia-telangiectasia (PMID: 9792409, 9887333, 10817650, 12815592, 21833744, 25980754, 27978560). This variant is also known as 839del10. ClinVar contains an entry for this variant (Variation ID: 186242). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Aug 20, 2020- -
Pathogenic, criteria provided, single submitterclinical testingNeuberg Centre For Genomic Medicine, NCGM-The frame (c.8395_8404del) variant has been reported previously in patients affected with Ataxia-telangiectasia (Li A, Swift M., 200). The p.Phe2799LysfsTer4 variant is novel (not in any individuals) in 1000 Genomes and has allele frequency of 0.002% in gnomAD database. This variant has been reported to the ClinVar database as Pathogenic/Likely Pathogenic. This variant causes a frameshift starting with codon Phenylalanine 2799, changes this amino acid to Lysine residue, and creates a premature Stop codon at position 4 of the new reading frame, denoted p.Phe2799LysfsTer4. Loss-of-function variants in ATM are known to be pathogenic (Huang et. al., 2013). For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:5
Pathogenic, criteria provided, single submitterclinical testingGeneDxDec 12, 2024Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Also known as 8395del10; This variant is associated with the following publications: (PMID: 10817650, 35534704, 33309985, 35892882, 36243179, 37024097, 36451132, 29906526, 32980694, 34637943, 25980754, 15039971, 27978560, 21833744, 30287823, 18718650, 30322717, 31285527, 9792409, 9887333, 22649200, 26896183, 29625052, 31948886, 33919281, 33436325, 32888943, 12815592, 28767289, 38355628) -
Likely pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicDec 21, 2022PM3, PVS1 -
Pathogenic, criteria provided, single submitterclinical testingInstitute of Medical Genetics and Applied Genomics, University Hospital TübingenOct 23, 2020- -
Pathogenic, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalAug 15, 2023- -
Pathogenic, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenOct 01, 2023ATM: PVS1, PM2 -
Familial cancer of breast Pathogenic:4
Pathogenic, criteria provided, single submitterclinical testingMyriad Genetics, Inc.Feb 02, 2024This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsFeb 27, 2024- -
Pathogenic, no assertion criteria providedclinical testingBRCAlab, Lund UniversityAug 26, 2022- -
Pathogenic, criteria provided, single submitterclinical testingGreenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic CenterMar 21, 2022PVS1, PM2, PM3 -
Hereditary cancer-predisposing syndrome Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsMay 28, 2024The c.8395_8404del10 pathogenic mutation, located in coding exon 56 of the ATM gene, results from a deletion of 10 nucleotides at nucleotide positions 8395 to 8404, causing a translational frameshift with a predicted alternate stop codon (p.F2799Kfs*4). This mutation has been reported in cohorts of individuals with classic ataxia-telangiectasia (Broeks A et al. Hum. Mutat. 1998;12:330-7; Sandoval N et al. Hum. Mol. Genet. 1999 Jan;8:69-79; Li A et al. Am. J. Med. Genet. 2000 May;92:170-7; Mitui M et al. Hum. Mutat. 2003 Jul;22:43-50) and two unrelated individuals diagnosed with sporadic pancreatic ductal adenocarcinoma at ages 35 and 55, respectively (Shindo K et al. J. Clin. Oncol. 2017 Oct;35:3382-3390). Of note, this alteration is also designated as 8385del10 in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Pathogenic, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthSep 19, 2022This variant deletes 10 nucleotides in exon 57 of the ATM gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with ataxia telangiectasia (PMID: 10817650, 12815592, 21665257, 21833744). This variant has also been reported in individuals affected with Lynch syndrome-associated cancer and/or polyps (PMID: 25980754, 27978560) and pancreatic cancer (PMID: 28767289, 35892882). This variant has been identified in 5/251232 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Pathogenic, criteria provided, single submittercurationSema4, Sema4Jan 26, 2021- -
ATM-related disorder Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesJul 17, 2024The ATM c.8395_8404del10 variant is predicted to result in a frameshift and premature protein termination (p.Phe2799Lysfs*4). This variant has been reported in multiple individuals with ataxia telangiectasia (Huang et al. 2018. PubMed ID: 29625052; Momozawa et al. 2018. PubMed ID: 30287823; Carter et al. 2018. PubMed ID: 30322717; Hutchings et al. 2019. PubMed ID: 31285527). This variant has also been reported in individuals with pancreatic cancer and colon cancer (Shindo et al. 2017. PubMed ID: 28767289; Yurgelun et al. 2015. PubMed ID: 25980754; Pearlman et al. 2017. PubMed ID: 27978560). Functional studies have shown this variant results in less than 10% of normal phosphorylation activity (Nahas et al. 2009. PubMed ID: 19147735). This variant is reported in 0.0033% of alleles in individuals of South Asian descent in gnomAD and is interpreted as pathogenic/likely pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/186242/). Frameshift variants in ATM are expected to be pathogenic. This variant is interpreted as pathogenic. -
Gastric cancer Pathogenic:1
Pathogenic, no assertion criteria providedresearchLaboratory for Genotyping Development, RIKENJul 01, 2021- -
Breast carcinoma Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingMedical Genetics Laboratory, Umraniye Training and Research Hospital, University of Health SciencesAug 20, 2021Invasive Ductal Carcinoma Estrogen Receptor: Positive Progesterone Receptor: Positive HER2 Receptor: Negative -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs786202800; hg19: chr11-108214064; API